Ulcerative Colitis

Eli Lilly’s mirikizumab and Pfizer’s etrasimod are expected to be approved by the FDA this year.

By activating the farnesoid X receptor, psyllium may have anti-inflammatory effects.

Authors of a study published in Gastroenterology say results show that an artificial intelligence-based, computer-aided model accurately differentiates disease remission from inflammation.

Guidelines recommend testing for calprotectin and lactoferrin in stool samples and C-reactive protein in the blood.

Crohn's disease and ulcerative colitis can affect food intake and lead to malabsorption of nutrients and intestinal bacterial overgrowth.

The classes with the strongest association with inflammatory bowel disease were those typically used to treat GI infections, nitroimidazoles and fluoroquinolones.

Research by Maria T. Abreu, M.D., and Jacob McCauley, Ph.D., should help fill a gap in the research of the genetics of inflammatory bowel disease, including ulcerative colitis.

A Swedish and a French company have treatments with novel mechanisms of action in late-stage development. Meanwhile, AbbVie, Janssen and Eli Lilly are vying to get the first interleukin-23 inhibitor for ulcerative colitis on the market.

Other adverse outcomes were not linked to histological inflammation, according to results of a Swedish study.

Cobitolimod from InDex, a Swedish company, and obefazimod, from Abivax, a French company, could be first-in-class medications for ulcerative colitis.

Stomach acid interferes with the effectiveness of probiotics taken as pills. Researchers are bioengineering probiotics in hopes of getting around that problem.